Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Integrative omics analysis of TP53 in multiple myeloma patients

Cristina De Ramón Sánchez, Elizabeta A Rojas, Irena Misieweicz, Maria García-Alvarez, Myriam Cuadrado, Sara Cristobal, Ignacio J Cardona-Benavides, Isabel M Isidro, Maria Calasanz, Miguel Alcoceba, Ramon Garcia-Sanz, Laura Rosiñol Dachs, Joaquin Martinez-Lopez, Joan Batista Blade Creixenti, Juan-Jose Lahuerta Palacios, Jesus San-Miguel, María-Victoria Mateos, Luis Antonio Corchete Sanchez, Norma Gutiérrez

Blood (2025) 146 (Supplement 1): 2162.

https://doi.org/10.1182/blood-2025-2162

Published: 2025

Journal Articles

Validation of the High-Risk Consensus Genomic Staging System in Newly Diagnosed Multiple Myeloma

Blood (2025) 146 (Supplement 1): 922.

https://doi.org/10.1182/blood-2025-922

Published: 2025

Journal Articles

Fixed-duration subcutaneous mosunetuzumab continues to demonstrate high rates of durable responses in patients with relapsed/refractory follicular lymphoma after ≥2 prior therapies: 3-year follow-up from a pivotal Phase II study

Blood (2025) 146 (Supplement 1): 5353.

https://doi.org/10.1182/blood-2025-5353

Published: 2025

Journal Articles

Fixed treatment duration mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior therapies: 5-year follow-up of a pivotal Phase II study

Blood (2025) 146 (Supplement 1): 5352.

https://doi.org/10.1182/blood-2025-5352

Published: 2025

Journal Articles

Spanish real-life practice confirms zanubrutinib as a safe and effective option in relapsed or refractory marginal zone lymphoma: Results of a cohort of 118 patients on behalf of GELTAMO.

Blood (2025) 146 (Supplement 1): 5350.

https://doi.org/10.1182/blood-2025-5350

Published: 2025

Journal Articles

EO2463 (EO) peptide immunotherapy combined with rituximab (R) for first-line treatment of low-tumor burden follicular lymphoma (FL): A feasibility evaluation in Study EONHL1-20/sidney (NCT04669171)

Blood (2025) 146 (Supplement 1): 3594.

https://doi.org/10.1182/blood-2025-3594

Published: 2025

Journal Articles

Comprehensive DNA/RNA-based targeted sequencing for molecular karyotyping and clonality assessment in newly diagnosed multiple myeloma patients

Blood (2025) 146 (Supplement 1): 2562.

https://doi.org/10.1182/blood-2025-2562

Published: 2025

Journal Articles

Transcriptional stratification reveals distinct molecular subtypes with treatment-specific outcomes in multiple myeloma patients from the GEM2017FIT trial

Blood (2025) 146 (Supplement 1): 496.

https://doi.org/10.1182/blood-2025-496

Published: 2025

Journal Articles

Toxicity, efficacy, and clinical management of bispecific antibodies in routine clinical practice: A real-world geltamo study in B-cell lymphoma

Mariana Bastos-Oreiro, Gloria Iacoboni, Pablo Manresa, Carolina Martinez, Laura Magnano, Ana Jiménez Ubieto, Sofía Vázquez-Díaz, Maria Jose Rodriguez Salazar, Maria Teresa Busnego Barreto, Raquel Del Campo, Pedro José Paúl Vidaller, Ilda Murillo, Eva Donato, Angel Serna, Hugo Daniel Luzardo Henríquez, Pilar Gomez Prieto, Elena Perez Ceballos, Begona Mendibil, Sergio Ramons, Ana Maria Garcia-Noblejas Moya, Sonia González De Villambrosia, Francisco Javier Diaz Galvez, Javier Lopez Jimenez, Paula Fernandez-Caldas, Antonio Gutierrez, Blanca Sanchez, Nazaret Dominguez, María Civeira Marin, Paola Villafuerte Gutiérrez, Izaskun Zeberio, Irati Ormezabal, Cristina Barrenetxea Lekue, Norma Gutiérrez, Sofia Martin-Consuegra, Samuel Romero Dominguez, Sofia Huerga, Nuria Golbano, Rosalia Riazza, Jose Antonio Hueso García, Pilar Martinez-Barranco, Belen Navarro Matilla, Lucia Villalon Blanco, Paula Ortega Nadal, Ana Torres Tienza, Víctor Navarro Garces, Pau Abrisqueta, Alejandro Martin Garcia-Sancho

Blood (2025) 146 (Supplement 1): 2732.

https://doi.org/10.1182/blood-2025-2732

Published: 2025

Journal Articles

Prognostic value of minimal residual disease detection by circulating tumor DNA in Hodgkin lymphoma.

Blood (2025) 146 (Supplement 1): 3541.

https://doi.org/10.1182/blood-2025-3541

Published: 2025

Journal Articles

Impact of frailty in survival of older patients with classical Hodgkin lymphoma: A retrospective, multicenter study from the spanish registry of lymphoma (RELINF) of the spanish group of lymphoma (GELTAMO)

Raul Cordoba, Maria Carmen Martinez Munoz, Rosa Maria Rodriguez Nunez, Blanca Sánchez-González, Miriam Moreno, Norma Gutiérrez, David Alonso Castronuño, Jimena Cannata, Pilar Gomez Prieto, Laurentino Benito, Tamara Torrado, Joan Buch, Juan Carlos Caballero, Nazaret Dominguez, Raquel Santiago Alonso, Isabel González-gascón-y-Marín, Maria Moya Arnao, Beatriz De La Cruz, Cecilia Carpio, Maria Dolores Gutiérrez-Meca Maestre, Luis Antonio López Gómez, Eukene Gainza, Maria Rocio Figueroa Mora, Paula Fernandez-Caldas, Mariana Bastos-Oreiro, Paola Villafuerte Gutiérrez, Samuel Romero Dominguez, Belen Navarro Matilla, Izaskun Zeberio, Emilia Pardal De La Mano, Antonio Gutierrez, Eva Donato, Javier Nuñez, Teresa Cobo, Begona Mendibil, Inigo Olazabal Eizaguirre, Maria Isabel Gomez Roncero, Cristina Barrenetxea, Haridian de la Nuez, Sara Ferrero, Roberto Trelles, Maria Garcia Roa, Luis Ignacio Sancho Val, Sofia Martin-Consuegra, Maria Luisa Bengochea, Carmen Alonso Prieto, Elena Ramila, Hugo Daniel Luzardo Henríquez, Maria Jesus Peñarrubia, Alfonso Ortiz, Ignacio Mahillo, Eva Domingo Domenech

Blood (2025) 146 (Supplement 1): 6264.

https://doi.org/10.1182/blood-2025-6264

Published: 2025

Journal Articles

EO2463 (EO) peptide immunotherapy in patients (pts) with newly diagnosed asymptomatic follicular lymphoma (FL) and marginal zone lymphoma (MZL): Study EONHL1-20/sidney (NCT04669171) primary endpoint lugano objective response analysis

Blood (2025) 146 (Supplement 1): 5377.

https://doi.org/10.1182/blood-2025-5377

Published: 2025

Journal Articles

FAM46C Controls Antibody Production By the Polyadenylation of Ig mRNAs and Inhibits Cell Migration in Multiple Myeloma

Ana B Herrero, PhD, Quwaider Dalia, Luis Antonio Corchete Sanchez, MSc, Ramon Garcia-Sanz, MD PhD, Norma Gutierrez, MD PhD

Blood (2018) 132 (Supplement 1): 1880.

https://doi.org/10.1182/blood-2018-99-111787

Published: 2018

Journal Articles

Curative Strategy for High-Risk Smoldering Myeloma (GEM-CESAR): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

Blood (2017) 130 (Supplement 1): 402.

https://doi.org/10.1182/blood.V130.Suppl_1.402.402

Published: 2017

Journal Articles

Impact of Next-Generation Flow (NGF) Minimal Residual Disease (MRD) Monitoring in Multiple Myeloma (MM): Results from the Pethema/GEM2012 Trial

Blood (2017) 130 (Supplement 1): 905.

https://doi.org/10.1182/blood.V130.Suppl_1.905.905

Published: 2017

Journal Articles

Defects In DNA Double-Strand Break Repair and Increased Alternative Non-Homologous End Joining Pathways In Multiple Myeloma: Implications For Genome Stability

Ana B Herrero, PhD, Jesus F San Miguel, MD, PhD, Norma Gutierrez, PhD, MD

Blood (2013) 122 (21): 4882.

https://doi.org/10.1182/blood.V122.21.4882.4882

Published: 2013

Journal Articles

Phenotypic, Transcriptomic and Genomic Characterization Of Clonal Plasma Cells (PCs) From Newly Diagnosed Patients With Light Chain Amyloidosis (AL)

Blood (2013) 122 (21): 1841.

https://doi.org/10.1182/blood.V122.21.1841.1841

Published: 2013

Journal Articles

Comparison Of Sequential Vs Alternating Administration Of Bortezomib, Melphalan and Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) In Elderly Patients With Newly Diagnosed Multiple Myeloma (MM) Patients: GEM2010MAS65 Trial

Maria-Victoria Mateos, MD, Ph.D, Joaquín Martínez-López, MD, PhD, Miguel T. Hernandez, Rafael Martinez, MD, Laura Rosiñol, MD, Enrique M. Ocio, Maria Asunción Echeveste, Jaime Pérez de Oteyza, Albert Oriol, Bargay Joan, Gironella Mercedes, Jesús Martín, Carmen Cabrera, Norma Gutierrez, PhD, MD, Martín María Luisa, Javier de la Rubia, Joan Blade, MD, Juan José Lahuerta, Jesús F San Miguel, MD, PhD

Blood (2013) 122 (21): 403.

https://doi.org/10.1182/blood.V122.21.403.403

Published: 2013

Journal Articles

Genomic Comparison Of Clonal B-Cells In Waldenstrom Macroglobulinemia (WM) Versus IgM MGUS

Blood (2013) 122 (21): 400.

https://doi.org/10.1182/blood.V122.21.400.400

Published: 2013

Journal Articles

Phenotypic and Genomic Analysis Of Multiple Myeloma (MM) Minimal Residual Disease (MRD) Clonal Plasma Cells (PCs)

Blood (2013) 122 (21): 402.

https://doi.org/10.1182/blood.V122.21.402.402

Published: 2013

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Integrative omics analysis of TP53 in multiple myeloma patients

Validation of the High-Risk Consensus Genomic Staging System in Newly Diagnosed Multiple Myeloma

Fixed-duration subcutaneous mosunetuzumab continues to demonstrate high rates of durable responses in patients with relapsed/refractory follicular lymphoma after ≥2 prior therapies: 3-year follow-up from a pivotal Phase II study

Fixed treatment duration mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior therapies: 5-year follow-up of a pivotal Phase II study

Spanish real-life practice confirms zanubrutinib as a safe and effective option in relapsed or refractory marginal zone lymphoma: Results of a cohort of 118 patients on behalf of GELTAMO.

EO2463 (EO) peptide immunotherapy combined with rituximab (R) for first-line treatment of low-tumor burden follicular lymphoma (FL): A feasibility evaluation in Study EONHL1-20/sidney (NCT04669171)

Comprehensive DNA/RNA-based targeted sequencing for molecular karyotyping and clonality assessment in newly diagnosed multiple myeloma patients

Transcriptional stratification reveals distinct molecular subtypes with treatment-specific outcomes in multiple myeloma patients from the GEM2017FIT trial

Toxicity, efficacy, and clinical management of bispecific antibodies in routine clinical practice: A real-world geltamo study in B-cell lymphoma

Prognostic value of minimal residual disease detection by circulating tumor DNA in Hodgkin lymphoma.

Impact of frailty in survival of older patients with classical Hodgkin lymphoma: A retrospective, multicenter study from the spanish registry of lymphoma (RELINF) of the spanish group of lymphoma (GELTAMO)

EO2463 (EO) peptide immunotherapy in patients (pts) with newly diagnosed asymptomatic follicular lymphoma (FL) and marginal zone lymphoma (MZL): Study EONHL1-20/sidney (NCT04669171) primary endpoint lugano objective response analysis

FAM46C Controls Antibody Production By the Polyadenylation of Ig mRNAs and Inhibits Cell Migration in Multiple Myeloma

Curative Strategy for High-Risk Smoldering Myeloma (GEM-CESAR): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

Impact of Next-Generation Flow (NGF) Minimal Residual Disease (MRD) Monitoring in Multiple Myeloma (MM): Results from the Pethema/GEM2012 Trial

Defects In DNA Double-Strand Break Repair and Increased Alternative Non-Homologous End Joining Pathways In Multiple Myeloma: Implications For Genome Stability

Phenotypic, Transcriptomic and Genomic Characterization Of Clonal Plasma Cells (PCs) From Newly Diagnosed Patients With Light Chain Amyloidosis (AL)

Comparison Of Sequential Vs Alternating Administration Of Bortezomib, Melphalan and Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) In Elderly Patients With Newly Diagnosed Multiple Myeloma (MM) Patients: GEM2010MAS65 Trial

Genomic Comparison Of Clonal B-Cells In Waldenstrom Macroglobulinemia (WM) Versus IgM MGUS

Phenotypic and Genomic Analysis Of Multiple Myeloma (MM) Minimal Residual Disease (MRD) Clonal Plasma Cells (PCs)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only